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TOPICAL MICRONUTRIENT DELIVERY 
SYSTEM AND USES THEREOF 
PRIORITY CLAIM 
This application claims priority to provisional application 
No. 60/197,828 ?led Apr. 14, 2000, incorporated by refer 
ence in its entirety. 
FIELD OF THE INVENTION 
This invention relates to a topical micronutrient delivery 
system. The system is useful in, e.g., delivery of desirable 
and/or necessary materials, such as micronutrients, to a 
subject in need of same. Therapeutic uses of the system are 
also described. 
BACKGROUND AND PRIOR ART 
The skin plays multiple roles in protection from environ 
mental insults. Environmental exposure results in the pro 
gressive deterioration of skin that is initially cosmetic but 
can lead to end stage diseases such as actinic keratosis and 
skin cancer. 
Skin deterioration results from damage to DNA and 
protein, and compelling evidence indicates that reactive 
oxygen species (“ROS” hereafter) are involved in the gen 
eration of DNA damage that results in the loss of genomic 
integrity of skin cells. Skin cells contain inherent mecha 
nisms for the maintenance of genomic integrity. A groWing 
body of evidence demonstrates that micronutrients including 
vitamins B6, B12, C, E, folate, and niacin are involved in the 
maintenance of genomic integrity via mechanisms ranging 
from scavenging ROS, to the repair of DNA damage. 
Sub-clinical micronutrient de?ciencies are prevalent even in 
advanced societies and micronutrient status decreases With 
age. 
Skin is a complex organ system, consisting of multiple 
layers. The uppermost, or “stratum corneum” layer consists 
of non-living material derived primarily from the terminal 
differentiation of epidermal keratinocytes, and provides a 
protective barrier for the underlying components of skin. 
The epidermis contains a number of cell types, although 
keratinocytes are the major cell type. Dermal ?broblasts are 
embedded Within a matrix comprised of collagen, elastin, 
proteoglycans, and other extracellular matrix molecules. 
Blood capillaries are found in the dermis, but the epidermis 
is non-vascular. 
As people age, progressively deleterious changes in skin 
appearance occur. The initial changes are the loss of smooth 
skin texture and the appearance of age spots, folloWed by 
changes in elasticity that lead to the appearance of skin 
Wrinkles. The age at Which these changes appear and the rate 
at Which one stage progresses to the next varies greatly from 
individual to individual. During the normal aging process, 
both the epidermis and dermis become thinner, With a loss 
of cell number and connective tissue, leading to the appear 
ance of ?ne Wrinkles. Ultraviolet (UV) irradiation from the 
sun causes photodamage that accelerates skin deterioration. 
In contrast to the thinning observed in sun-protected skin, 
photodamaged skin has a thickened and rough appearance 
With an increase in deeper skin Wrinkling. Photodamage also 
causes end-stage skin deterioration, including pre-malignant 
lesions termed actinic keratosis, and skin cancer. 
Compelling evidence noW indicates that oxidative stress, 
de?ned as an abnormal accumulation of ROS, is involved in 
the pathophysiology of skin deterioration. ROS include 
superoxides, the hydroxyl radical, hydrogen peroxide, sin 
glet oxygen, nitric oxide, peroxynitrite, and hypochlorite. 
See, e.g., Simonian, et al., Ann. Rev. Pharmacol. Toxicol. 
36:83—106 (1996), incorporated by reference. All cells are 
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exposed to ROS during the normal course of energy 
metabolism, via environmental exposure and/or immune 
surveillance. While ROS are involved in normal cell signal 
ing pathWays, elevation of ROS during oxidative stress 
disrupts signaling pathWays, often resulting in cell death by 
apoptosis or necrosis. Thus, it is likely that ROS are 
involved in the loss of cell numbers observed even in 
sun-protected skin over time. Exposure to the ultraviolet 
rays of sunlight is a major source of skin oxidative stress. 
TWo major targets for damage by ROS in skin are DNA and 
protein. DNA damage is of particular interest in that unre 
paired damage can lead to the loss of skin cells and to an 
altered function of cells that survive genotoxic stress. 
While some changes in skin during aging can not be 
avoided, much of the skin deterioration that occurs at an 
early age is avoidable. Skin cells contain a number of 
protective mechanisms for the prevention and repair of 
damage to DNA and proteins caused by ROS. First, a 
number of intracellular molecules, including glutathione and 
the antioxidant vitamins C and E, play key roles in scav 
enging ROS before they can react With cellular macromol 
ecules. Indeed, the antioxidant vitamins have already found 
application in the prevention of skin deterioration, as they 
are components of many skin creams. Second, cells contain 
complex mechanisms for the maintenance of genomic integ 
rity. Of particular interest herein is the accumulating evi 
dence for the involvement of micronutrients in maintenance 
of DNA structure and in DNA repair mechanisms. There are 
approximately 40 micronutrients that are required, in small 
amounts, to maintain normal human metabolism (Ames, 
Ann. NY. Acad. Sci 889: 87—106 (1999), incorporated by 
reference). For many of these micronutrients, a siZeable 
portion of the population consumes signi?cantly less of the 
micronutrient than What has been established as the recom 
mended daily intake see Wilson, et al. Data Tables: Com 
bined Results from USDA’s 1994 and 1995 continuing 
survey of food intakes by individuals and 1994 and 1995 diet 
and health knoWledge survey (USDA/ARS Food Surveys 
Research Group, Beltsville Human Nutrition Research 
Center, Riverdale, Md. (1997), incorporated by reference. 
The percentage of the US. population that is de?cient in a 
particular micronutrient ranges from 2 to 20%. Ames, supra. 
To complicate matters, micronutrient status deteriorates fur 
ther With increasing age. Bates, et al., Br. J. Nutr 82(1):7—15 
(1999). Much of our knoWledge about the relationship 
betWeen micronutrients and various diseases such as cancer 
derives from measurements of micronutrient levels in 
plasma. While there is much to learn regarding plasma 
micronutrient levels and target tissue levels, there is evi 
dence that de?ciencies observed in plasma are also observed 
in skin. See Peng, et al., Canc. Epidermiol Biomarkers Prev 
2(2): 145—50 (1993). This is not surprising, since the epi 
dermal layer of skin does not contain blood vessels, making 
delivery of dietary micronutrients to skin inef?cient. Of 
particular concern for skin deterioration are observations 
that micronutrient de?ciencies can mimic radiation- and 
chemical-induced DNA damage, by effecting single-and 
double-strand breaks and/or oxidative lesions. Ames, supra. 
Speci?cally, de?ciencies in folic acid, B12, B6, niacin, 
vitamin C, vitamin E, iron, and Zinc can result in DNA 
damage. Ames, supra. For each of these micronutrients, 
there are knoWn metabolic pathWays that describe the ratio 
nale by Which a de?ciency results in DNA damage in the 
absence of genotoxic stress. Additionally, the micronutrient 
de?ciencies Would be expected to exacerbate the deleterious 
effects of genotoxic stress. The above information indicates 
that improving the micronutrient status of skin cells is 
desirable, as this Will improve the health of skin and likely 
retard skin deterioration. 
It is an object of the invention to provide a tropical 
delivery system Which is useful in making micronutrients 
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available, or making these micronutrients available in 
greater quantities than possible in the past. 
It is a further object of the invention to arrest or to prevent 
deterioration of organs such as skin, by making micronutri 
ents available in amounts sufficient to arrest or to prevent the 
deterioration. 
HoW this is accomplished Will be seen from the disclosure 
Which folloWs. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts the skin, in cross section, in combination 
With an illustration of the delivery system of the invention. 
FIG. 2 elaborates an embodiment of the invention. 
FIG. 3 outlines the results of an experiment designed to 
determine the efficacy of co-esters in modulating delivery of 
active compounds. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The topical delivery system of the invention takes into 
consideration the tWo distinct barriers that in?uence the 
delivery of micronutrients to skin, i.e., the lipophilicity of 
stratum corneum, and skin metabolic activity. The micro 
nutrient delivery system of the invention is outlined in FIG. 
1. In brief, the partitioning of the micronutrient in and out of 
the stratum corneum is controlled by the nutrient esters With 
optimal lipophilicity for such partitioning. These are 
described, infra. The term “pronutrient” is used to describe 
these compounds. Further, the rate and site of inetabolic 
conversion of pronutrients is controlled by the use of inac 
tive companion co-esters as described infra. Several features 
are required for this delivery system to function optimally. 
FIG. 2 shows a multiple compartment model that served as 
the frameWork for the development of these criteria. The 
model micronutrient used is niacin, but the skilled artisan 
Will realiZe that the information disclosed is relevant to a 
Wide variety of micronutrients as described in more detail 
infra. 
The highly lipophilic nature of the stratum corneum 
dictates that the desired micronutrient must be sufficiently 
lipophilic to effectively partition into the stratum corneum 
from the donor compartment, Which may be a skin cream or 
lotion (#1 in FIG. 2). This necessitates the preparation of 
distinct lipophilic pronutrients, as most micronutrients of 
interest are too hydrophilic to meet this criterion. As 
described in more detail infra, the required lipophilicity 
needed for diffusion from the stratum corneum into the 
epidermis predict that ef?cacious pronutrients should be 
sufficiently lipophilic to rapidly partition from the cream or 
lotion into the stratum corneum. Esters of micronutrients are 
used herein, as this alloWs lipophilic derivatives to be 
prepared and also alloWs their efficient bioconversion fol 
loWing diffusion out of the stratum corneum into the epi 
dermis. 
The lipophilicity of the pronutrients should alloW them to 
be formulated in, e.g., skin creams or lotions, and the ester 
linkages should be very stable in these formulations. 
Although the non-derivatiZed micronutrient Would be 
expected to partition very sloWly into the stratum corneum 
(#2 in FIG. 2), a pronutrient that is very stable is high 
desirable. The esters disclosed herein are pronutrients that 
are stable to chemical hydrolysis under aqueous conditions, 
as Well When formulated in a cream or lotion. 
The pronutrient must partition into the epidermis at a 
relatively sloW rate to achieve sustained delivery to the 
cellular components of skin With minimal systemic delivery 
(#3 in FIG. 2). Acorrelation betWeen skin permeability (PB) 
and the physicochemical properties of the drug, such as 
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octanol/Water partition coefficient (Pod/W) are of value in 
predicting drug transport across skin. A linear correlation 
betWeen skin permeability (Log PB) of many compounds 
and their logarithm of Pod/W has been established and is Well 
knoW in the art. Deviations from this relationship are 
observed for very hydrophilic and extremely lipophilic 
compounds. Compounds With optimal lipophilicity for 
delivery of a micronutrient to the cellular components of 
skin are disclosed herein. For niacin, e.g., as the model 
micronutrient, a series of alkyl esters of niacin Were pre 
pared and their relative lipophilicity Was determined. Next, 
the efficacy of these pronutrients in delivering niacin to the 
cellular components of skin by measuring the bioactive form 
of niacin (NAD) folloWing topical application thereof, using 
established models. 
It is believed that short chain esters may have an intrinsic 
?ux from the stratum corneum that is too rapid for sustained 
delivery to skin, i.e., systemic delivery Will be favored. 
LikeWise, a very long chain derivative is predicted to have 
a lipophilicity that Will have an intrinsic ?ux that is too sloW 
for effective delivery. The lipophilicity of a number of neW 
niacin esters disclosed in Ser. No. 09/452,617, along With 
some commercially available esters is shoWn in Table 1 
infra, together With values for the tWo, unmodi?ed 
molecules, i.e., nicotinic acid and nicotinamide. The lipo 
philicity is reported as log P values, Where P refers to the 
octanol/Water partition coefficient, described supra. Table 1 
also shoWs that nicotinic acid and niacin esters With log P 
values of less than 6 cause vasodilation at the site of topical 
application. This demonstrates that these nicotinic acid and 
niacin esters are delivering niacin at a rate that exceeds the 
minimum concentration needed to cause vasodilation of the 
endothelial cells of the blood capillaries. Niacin esters With 
log P values greater than 6 do not cause dilation. Nicotina 
mide does not cause vasodilation, but its log P value also 
predicts that it Will deliver nutrient too rapidly to alloW the 
cellular components of skin to assimilate it and convert it to 
its bioactive form NAD. To determine the optimum physical 
properties of pronutrient for topical delivery to the cells of 
the skin, niacin esters With log P values ranging from 6.6 to 
9.2 Were examined by determination of the active form of 
niacin, NAD in the skin folloWing application of the lotion. 
Results from a typical experiment are shoWn in Table 2, 
Where niacin pronutrients formulated at 1% Were topically 
applied to the backs of hairless mice once a per day for three 
days. After three days, skin Was removed from both the site 
of application and from the abdomen of each animal, and the 
NAD content Was analyZed. Analysis of skin from the backs 
of the animals demonstrated that niacin esters of 12, 14, and 
16 carbons resulted in an increased NAD content, although 
the 14 carbon ester Was the most effective. In further 
experiments, it Was determined that a niacin ester With a 
carbon side chain of 18, and a log P value of 9.7 Was less 
effective that the ester With a 16 carbon side chain. Further, 
it Was shoWn that topical application of niccotinamide, 
Which has a log P value of —0.34, had no effect on skin cell 
NAD content. The results of Table 2 also shoW that the 
delivery Was topical for the 14 and 16 carbon esters, as there 
Was no increase in the NAD content of the abdomen Where 
the pronutrient Was not applied. Topical application of the 12 
carbon ester did shoW some delivery to the abdomen, Which 
is consistent With the suggestion, supra that this compound 
should have the fastest rate of delivery of the compounds 
compared in this experiment. 
The delivery approach disclosed herein involves the bio 
conversion of the pronutrient to the desired micronutrient by 
the action of skin esterases. Studies on the esterase distri 
bution of skin have shoWn that the stratum corneum has little 
or no activity, the epidermis has the highest activity and the 
dermis has reduced activity relative to the epidermis. See 
Sugibayashi, et al. J. Controlled Release 62:201—208 (1999) 
US 6,464,992 B2 
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incorporated by reference. Delivery should be possible 
Whether the bioconversion is extracellular (#4 & 5, FIG. 2) 
or following uptake by the target cells (#6 & 7 in FIG. 2) as 
cells contain speci?c transport systems for micronutrients 
and the lipophilicity of the pronutrients should make them 
readily bioavailable via passive diffusion. Since the stratum 
corneum contains little or no esterase activity, the rate of 
disappearance of a pronutrient from the stratum corneum 
depends only on the rate of diffusion, Which can be 
described by Fick’s second laW of diffusion: 
Where dc/dt is the change in pronutrient concentration over 
time, CSC is the pronutrient concentration in the stratum 
corneum and D SC is the diffusion coef?cient from the 
stratum corneum. 
In the epidermis and dermis, Where both diffusion and 
metabolism are occurring simultaneously, both diffusion and 
metabolism must be considered. Thus the rate of disappear 
ance from these compartments can be described by: 
dCproN/dt=DproNd2CproN/d2x_ Vm1l>c(x) 'CproN/ Km +CproN 
Where CpmN and DPrON are the concentration and diffusion 
co-ef?cient of the pronutrient in the epidermis or dermis and 
Vmax(x) is maximum rate of metabolic conversion at posi 
tion X, and Km is the Michaelis-Menten constant. 
The use of ester derivatives of micronutrients is appli 
cable to a Wide range of micronutrients, some of Which are 
presented in Table 3. The micronutrients shoWn contain 
either an acid functionality, an alcohol functionality, or both. 
Micronutrients containing an acid functional group can be 
esteri?ed to a long chain alcohol to alloW formation of the 
desired lipophilicity for topical delivery. Micronutrients 
With an alcohol functionality can be esteri?ed to a long chain 
acid to achieve the desired lipophilicity. 
It is preferred to combine the esters described supra, With 
inactive co-esters, as these alloW modulation of nutrient 
delivery to speci?c locations Within skin. The high esterase 
content in the epidermis favors the delivery of topically 
applied pronutrients to cells present in the epidermis. While 
delivery to cells in the epidermis is a major goal of the 
topical delivery system, it is also highly desirable to achieve 
delivery to dermal ?broblasts and to endothelial cells in 
blood capillaries in the skin. Enhancing delivery to the 
dermis and blood capillaries can be achieved by the use of 
inactive co-esters that can be used to modulate the extent of 
bioconversion of pronutrients in the epidermis. For co-esters 
to modulate the rate of conversion of pronutrients in the 
skin, tWo criteria must be met. First, the co-ester must have 
lipophilicity similar to that of the pronutrient, such that ?ux 
from the stratum corneum of the pronutrient and co-ester is 
similar. Second, the co-ester must effectively compete With 
the pronutrient for bioconversion by the skin esterases. At 
concentrations of pronutrient beloW enZyme saturation, 
co-esters Will competitively inhibit the metabolic conversion 
in the epidermis (#4 in FIG. 2) and alloW the pronutrient to 
pass intact to the dermis (#5 in FIG. 2) for conversion and 
delivery. This approach minimiZes the required dose of 
pronutrients and provides a good targeted delivery system to 
the dermis. The targets of delivery in the dermis include both 
dermal ?broblasts and capillary endothelial cells. For the 
dermal ?broblasts, the aim is to deliver niacin for conversion 
to AND. For the capillary endothelial cells, the knoWn 
vasodilation properties of niacin may be useful for increas 
ing blood How in the dermis, increasing the supply of 
oxygen and other essential nutrients and increasing the 
ef?ciency of removal of carbon dioxide and other metabolic 
end products. An experiment demonstrating the use of 
co-esters to modulate delivery is shoWn in FIG. 3. For this 
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experiment, the eight carbon ester of niacin (octyl 
nicotinate) for delivery of niacin to the endothelial cells of 
blood capillaries, in order to increase the oxygen content of 
skin. In this experiment, a transcutaneous oxygen monitor 
has been used to determine oxygen content in the skin. A 
lotion containing the test compound Was topically applied 
for thirty minutes. The lotion Was then removed and the 
transcutaneous oxygen monitor Was placed on the surface of 
the skin. The control experiment shoWed that the oxygen 
content of skin (P02) shoWs a value of 4 mm, demonstrating 
the relatively loW oxygen content Was increased. The dura 
tion of the increase is not long because the lotion must be 
removed in order to make the oxygen measurement. Butyl 
benZoate Was chosen as the co-ester. Butyl benZoate has a 
log P value of 3.5 compared to a log P value of 4.8 for octyl 
nicotinate. FIG. 3 shoWs that a formulation containing both 
octyl nicotinate and butyl benZoate blocked the increase in 
skin oxygen content elicited by octyl nicotinate alone, 
demonstrating modulation of delivery of the pronutrient by 
the co-ester. 
The experiments Which folloW set forth the invention in 
greater detail, but should not be construed as limiting the 
invention in any Way. 
EXAMPLE 1 
Nicotinic acid esters Were synthesiZed in accordance With 
Ser. No. 09/452,617, ?led Dec. 1, 1999, incorporated by 
reference. In brief, nicotinoyl chloride Was combined With 
triethylamine (TEA), dimethylaminopyridine (DMAP), and 
various alkyl alcohols, under nitrogen. Esters resulting from 
the synthesis Were separated via silica gel column 
chromatography, and converted to HCl salts for further 
puri?cation, using standard methods. The purity Was con 
?rmed via thin layer chromatography, and 1H-NMR. 
The Pact/W values for these compounds Were determined in 
accordance With Harnisch, et al., J. Chromatog. 
282:315—332 (1983), incorporated by reference. In brief, 
this HPLC method determines capacity factor (“K‘”) for 
each pronutrient, and also establishes a linear relationship 
betWeen the logarithm of Pact/W and the logarithm of K‘, for 
short chain pronutrients. Rate of hydrolysis of candidate 
nicotinic acid ester derivatives Was determined, in aqueous 
phosphate buffer, at physiological pH (7.4), With incubation 
at 37° C. Rate of pronutrient disappearance from solution 
Was monitored, by HPLC, at 254 nm. 
EXAMPLE 2 
In animal experiments, female hairless mice (HRS-J, 6—8 
Weeks old), received daily topical application of nicotinic 
acid esters, using 200 mg of commercially available “Vani 
cream” lotion, at a 1.0% (Wt/Wt) concentration, for three 
days. Control animals received Vanicream only. The lotions 
Were applied, daily, for one Week. 
Animals Were euthaniZed, and dorsal and ventral skin 
samples Were then froZen in liquid nitrogen, and stored at 
—80° C. In order to analyZe NAD and protein content, tissue 
samples Were homogeniZed, in 0.5M, ice cold HClO4, and 
then centrifuged at 3000 rpm for 15 minutes. The resulting 
supernatants Were neutraliZed With ice-cold 2M KOH/ 
0.66M KH2PO4, in order to determine NAD. The NAD Was 
determined in accordance With Jacobson, et al., Meth. EnZy 
mol. 280: 221—230 (1997) incorporated by reference, While 
a commercially available BCA method Was used for protein 
determination. 
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TABLE 1 
Properties of Niacin Pronutrients 
8 
ranging from about 6.5 to about 8.5, more preferably from 
about 7.0 to about 8.0. As Was shoWn in the examples set 
forth herein, in the case of the niacin esters, a log P of about 
7.6 Was ideal. For niacin this resulted from an ester With a 
14 carbon side chain. It Will be understood by the skilled 
Alkyl Carbon Chain Length Log P Value Erythematous Response artisan that the preferred structures Will vary from nutrient to 
Nicotinamide (NO Side Chain) _O_34 NO nutrient or micronutrient to micronutrient, but the log P 
Nicotinic Acid (No side chain) -0_46 Yes values Will control. The computation of log P values should 
1 Carbon 0-84 Yes be carried out as described herein. The log P values recited 
2 carbons 1-3 Yes herein are predictive of the rate of partitioning of the 
4 carbons 2.4 Yes 10 ~ ~ ~ ~ ~ ~ ~ 
6 carbons 35 Yes materials of interest. Many micronutrients of interest exist in 
8 carbons 48 Yes esteri?ed form. Processes for esterifymg others are knoWn to 
10 carbons 58 Slight the art, and need not be set forth here. 
12 carbons 6-6 NO As indicated, supra, it is preferred that the micronutrient 
13 carbons 7'5 N0 of interest be combined With a “co-ester.” This co-ester, as 
i; g 15 used herein, refers to a compound Which is an ester, and is 
16 carbons 92 NO less lipophilic than the micronutrient, so that it Will migrate 
18 carbons 9.7 No slightly faster from, e.g., the stratum corneum so as to 
occupy esterases, such as skin esterases, thereby permitting 
diffusion of the micronutrient into the loWer layers of the 
TABLE 2 
Skin NAD content following topical application 
of niacin pronutrients 
Skin NAD content of back Skin NAD content of abdomen 
Alkyl Group Log P pmol NAD/mg tissue % pmol NAD/mg tissue % 
Lotion only — 91.4 +/- 18.4 100 60.4 +/- 15.2 100 
12 Carbons 6.6 129.4 +/- 15.4 141 82.6 +/- 14.8 137 
14 Carbons 7.6 165.7 +/- 12.0 181 55.8 +/- 13.8 92 
16 Carbons 9.2 109.5 +/- 8.3 120 52.1 +/- 10.4 86 
skin. In quantitative terms, it is preferred that the lipophi 
TABLE 3 35 licity of the co-ester should be Within a factor of about 20, 
i.e., have a log P Which differs from the value for the 
Micronutrient Candidates for Generation of Pronutrient Esters micronutrient With Which it is coadministered or formulated 
by from about 0.5 to about 1.5, preferably by about 1.0 to 
Contain Alcohol Group Contain Carboxylic Acid Group about 1_5_ 
Vitamin B6 Niacin 40 Formulations as described above are covered by the 
Folic Acid Folic Acid invention, as are methods for delivering a micronutrient to 
Vitamin B12 Lipoic Acid a subject, via administering a combination of the micronu 
Pantothenic acid Pantothenic acid trient and the co-ester, in an amount sufficient to facilitate 
Carnitine Carnitine delivery of said micronutrient. In practice, the delivery 
Ribf’?fivin system described herein can be administered to a site of 
Ublqumones 45 injury, thus being used therapeutically, and/or it can be 
administered prophylactically, i.e., prior to exposure of the 
The foregoing sets forth the features of the invention, 5km and/Or Organ to lhsuh’ gehotoxlc Stress’ 6t?‘ The for' 
Which relates, inter alia, to systems and methods for delivery mulahohs can .be prepared Such that they Vary 1h Strength‘ 
of nutrients, such as micronutrients, to a subject. Preferably, The cohcehtrahoh Should range from about 0'005% to about 
these are topical delivery systems, in that they are formu- 50 50%’ more preferably from about 0'005% to 25%’ and 
lated for administration in the same manner as are other mOStPrefGrabIY from abpht 001% to abOut1'0% by Welght 
topical formulations. In addition to creams and lotions, of Sald apphed composlhoh' _ _ _ 
topical formulations Such as Shampoos, liquids Such as eye 'Other features of the invention Wlll be clear to the skilled 
Washes, balms and sticks such as lip balms and deodorant amsan and need not be Set forth hereln 
sticks, mouthWashes and gavages, soaps, suppositories, 55 The terms and expressions Which have been employed are 
patches, bandages, suturing threads, coated implant devices, used as terms of description and not of limitation, and there 
and any other type of system designed for topical application is no intention in the use of such terms and expressions of 
are a part of the invention. Preferably, the formulation is excluding any equivalents of the features shoWn and 
designed for application to, e.g., skin or other organs, such described or portions thereof, it being recognized that vari 
as liver, lungs, stomach, etc., scalp, eyes, blood vessels, and ous modi?cations are possible Within the scope of the 
so forth. 6O invention. 
The micronutrient used in the formulations may be any of We claim: 
those referred to by Ames, et al., supra, such as those set out 1. A method for delivering a nutrient to a subject, com 
in table 3. Preferably, the micronutrient is one Which con- prising topically applying to said subject a composition 
tains an acid moiety (e.g., ascorbic acid), an alcohol moiety, Which comprises said nutrient, in the form of an ester, and 
or both. It is also preferred that the alcohol moiety or 65 a co-ester Which inhibits esterases and is less lipophilic than 
moieties of the micronutrient be in esteri?ed form. These 
esteri?ed forms of micronutrients should have a log P value 
the ester form of said micronutrient, in an amount sufficient 
to facilitate delivery of said nutrient to cells of said subject. 
US 6,464,992 B2 
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2. The method of claim 1, wherein said nutrient is a 
micronutrient. 
3. The method of claim 2, Wherein said micronutrient is 
a micronutrient Which contains an alcohol group. 
4. The method of claim 3, Wherein said micronutrient is 
vitamin B6, folic acid, vitamin B12, pantothenic acid, 
carnitine, ribo?avin or an ubiquinone. 
5. The method of claim 2, Wherein said micronutrient is 
a micronutrient Which contains a carboXylic acid group. 
6. The method of claim 5, Wherein said micronutrient is 
ascorbic acid, niacin, folic acid, lipoic acid, pantothenic 
acid, or carnitine. 
7. The method of claim 6, Wherein said micronutrient is 
niacin. 
8. The method of claim 7, Wherein said niacin is admin 
istered in the form of an ester having an alkyl side chain of 
from 12—16 carbon atoms. 
9. The method of claim 8, Wherein said alkyl side chain 
consists of 14 carbon atoms. 
10. The method of claim 1, Wherein said co-ester has a 
lipophilicity log P value Which differs from said micronu 
trient from about 0.5 to about 1.5. 
11. The method of claim 1, Wherein said ester and co-ester 
have log P values Which differ from each other by about 1.3. 
12. The method of claim 1, Wherein said ester has a log 
P value of from about 6.5 to about 8.5. 
13. The method of claim 12, Wherein said ester has a log 
P value of from about 7 to about 8. 
14. The method of claim 1, Wherein said composition is 
in the form of a cream, a lotion, a shampoo, an eye Wash, a 
balm, a stick, a mouthWash, a gavage, a soap, a suppository, 
a bandage, a suturing thread or an implant device. 
15. The method of claim 1, Wherein said subject suffers 
from a de?ciency of said micronutrient. 
16. The method of claim 15, comprising administering 
said composition to a site of injury on said subject. 
17. The method of claim 1, Wherein said co-ester is butyl 
benZoate. 
18. Composition useful in delivering a nutrient to a 
subject, comprising: an esteri?ed form of said nutrient 
and (ii) a co-ester Which inhibits esterases Wherein said 
co-ester is less lipophilic than the esteri?ed form of said 
nutrient. 
19. The composition of claim 18, Wherein said nutrient is 
a micronutrient. 
20. The composition of claim 18, in a form suitable for 
topical administration. 
21. The composition of claim 19, Wherein said micronu 
trient contains an alcohol group. 
22. The composition of claim 19, Wherein said micronu 
trient contains a carboXylic acid group. 
23. The composition of claim 21, Wherein said micronu 
trient is vitamin B6, folic acid vitamin B12, pantothenic 
acid, carnitine, ribo?avin, or an ubiquinone. 
24. The composition of claim 22, Wherein said micronu 
trient is ascorbic acid, niacin, folic acid, lipoic acid, pan 
tothenic acid, or carnitine. 
25. The composition of claim 24, Wherein said micronu 
trient is niacin. 
1O 
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26. The composition of claim 25, Wherein said niacin is in 
the form of an ester having an alkyl side chain of from 12—16 
carbon atoms. 
27. The composition of claim 26, Wherein said alkyl side 
chain consists of 14 carbon atoms. 
28. The composition of claim 18, Wherein said co-ester is 
benZyl benZoate. 
29. The composition of claim 18, Wherein and (ii) have 
log P values Which differ from each other by about 1.3. 
30. The composition of claim 18, Wherein has a log P 
value of from about 6.5 to about 8.5. 
31. The composition of claim 18, Wherein has a log P 
value of from about 7 to about 8. 
32. A method for delivering a nutrient to a subject 
suffering from de?ciency of said nutrient comprising topi 
cally applying to said subject a composition Which com 
prises said nutrient, in the form of an ester, and a co-ester 
Which inhibits esterases, in an amount su?icient to facilitate 
delivery of said nutrient to cells of said subject. 
33. The method of claim 32, Wherein said nutrient is a 
micronutrient. 
34. The method of claim 33, Wherein said micronutrient 
is a micronutrient Which contains an alcohol group. 
35. The method of claim 34, Wherein said micronutrient 
is vitamin B6, folic acid, vitamin B12, pantothenic acid, 
carnitine, ribo?avin or an ubiquinone. 
36. The method of claim 33, Wherein said micronutrient 
is a micronutrient Which contains a carboXylic acid group. 
37. The method of claim 36, Wherein said micronutrient 
is ascorbic acid, niacin, folic acid, lipoic acid, pantothenic 
acid, or carnitine. 
38. The method of claim 37, Wherein said micronutrient 
is niacin. 
39. The method of claim 38, Wherein said niacin is 
administered in the form of an ester having an alkyl side 
chain of from 12—16 carbon atoms. 
40. The method of claim 39, Wherein said alkyl side chain 
consists of 14 carbon atoms. 
41. The method of claim 32, Wherein said co-ester is less 
liphophilic than the ester form of said micronutrient. 
42. The method of claim 41, Wherein said co-ester has a 
lipophilicity log P value Which differs from said micronu 
trient from about 0.5 to about 1.5. 
43. The method of claim 32, Wherein said ester and 
co-ester have log P values Which differ from each other by 
about 1.3. 
44. The method of claim 32, Wherein said ester has a log 
P value of from about 6.5 to about 8.5. 
45. The method of claim 44, Wherein said ester has a log 
P value of from about 7 to about 8. 
46. The method of claim 32, Wherein said composition is 
in the form of a cream, a lotion, a shampoo, an eye Wash, a 
balm, a stick, a mouthWash, a gavage, a soap, a suppository, 
a bandage, a suturing thread or an implant device. 
47. The method of claim 32, comprising administering 
said composition to a site of injury on said subject. 
48. The method of claim 32, Wherein said co-ester is butyl 
benZoate. 
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